ArticleAnnals of medicine and surgery (2012)2025
Exploring the Systemic Immune-Inflammation Index as a novel biomarker for nonalcoholic fatty liver disease: a systematic review and meta-analysis.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07431593 (Clinical Significance and Prognostic Value of Systemic Immune Inflammation Index and Systemic Inflammation Response Index in Obesity and Associated Metabolic Complications), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Significance and Prognostic Value of Systemic Immune Inflammation Index and Systemic Inflammation Response Index in Obesity and Associated Metabolic Complications
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nonalcoholic fatty liver disease (NAFLD) represents one of the most prevalent chronic hepatic disorders globally and is intricately associated with metabolic dysregulation and persistent systemic inflammation. The Systemic Immune-Inflammation Index (SII) has emerged as a promising noninvasive indicator for various inflammation-mediated conditions, including NAFLD. This meta-analysis was undertaken to assess the association between SII and NAFLD. Methods: Observational studies identified through a systematic search of PubMed, Web of Science, Embase, and Scopus up to February 2025 that examined the association between SII and NAFLD were considered eligible for inclusion. Quantitative synthesis of the data was conducted through meta-analytic techniques employing a random-effects model to derive pooled effect estimates, thereby accounting for potential heterogeneity across studies. Results: The meta-analysis demonstrated a statistically significant association between higher SII levels and NAFLD. When SII was analyzed as a continuous variable, the pooled effect size was significant (Hedges' Conclusions: SII shows a significant association with NAFLD and may serve as a valuable, noninvasive biomarker for early detection and risk stratification. Despite promising results, the presence of heterogeneity and possible publication bias highlights the need for more standardized and longitudinal research to validate SII's clinical utility in NAFLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.